Key facts
- PrimeGene (Beijing)’s last known valuation is $248.0M (Jan 2025).
- It has raised $85.6M; the latest was Later Stage VC ($15.9M) in Jan 2025.
- Notable investors include Beijing State-owned Capital Operation and Management, K2VC, Shun Xi Fund, Lapam Capital, Capital Science and Technology Development Group — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for PrimeGene (Beijing)
- ·The full record, as it builds
Funding rounds
No funding rounds for PrimeGene (Beijing) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PrimeGene (Beijing)
Operator of an innovative pharmaceutical company intended to be specialized in innovative drug research, clinically valuable generic drug development and pharmaceutical industrialization. The company focuses on new drug discovery, R&D and commercialization featuring immune/inflammatory diseases and external use, providing new drugs for skin, ophthalmology, rhinology and respiratory system.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Employees
- 90
- Website
- primegene.net/
- Ownership
- Privately Held (backing)
PrimeGene (Beijing) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PrimeGene (Beijing) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PrimeGene (Beijing) in its N-PORT filings yet. We sweep new filings monthly.